IMM-H014

DRUG2 trials

Sponsors

Changchun Intellicrown Pharmaceutical Co. LTD

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Nonalcoholic Steatohepatitis (NASH)

Phase 1

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

RecruitingNCT06216041

Changchun Intellicrown Pharmaceutical Co. LTDNonalcoholic Steatohepatitis (NASH)

Start: 2023-12-06End: 2025-08-01Target: 138Updated: 2025-04-11

To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH

Not yet recruitingNCT07016633

Changchun Intellicrown Pharmaceutical Co. LTDMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Start: 2025-06-10End: 2027-12-01Target: 40Updated: 2025-06-13